Servier Pharmaceuticals shared on LinkedIn:
“We’re pleased to share extended follow-up data from our Phase 3 trial in mutant isocitrate dehydrogenase 1 or 2 (IDH1/2) glioma.
These results, presented at the Society for Neuro-Oncology (SNO) Annual Meeting, build on our understanding of how targeted treatment can help patients living with IDH-mutant glioma and underscore the importance of continued research in this rare disease.”
Learn more: Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO.”
You can also read: Servier Announces Updated Four-Year Results for OJEMDA in Pediatric Low-Grade Glioma.